Talkspace, Inc.
NASDAQ:TALKMedical - Care Facilities
+$0.01 today
- Market cap
- $879.44M
- Beta
- 1.07
- P/E (TTM)
- 749.9
- EPS (TTM)
- $0.01
Volume 2.41M
Average 2.55M
TALK EBITDA Margin
EBITDA as a percentage of revenue.
Talkspace, Inc.NASDAQ: TALK
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to -7.5%
EBITDA Margin was -7.5% in Q1 FY2026, down 9.6 pp from a year earlier. On a trailing-twelve-month basis it was 2.6%, up 0.4 pp year over year. Over 3 fiscal years it widened by 70.2 pp.
Context
- EBITDA Margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 2 analysts of -24.9% for the fiscal year ending Dec 2026, down from 4.9% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -7.5%-16.9 pp QoQ
- Last fiscal yearDec 2025
- 4.9%+3.8 pp YoY
- LTMMar 2026
- 2.6%+0.4 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 4.9%
- Year-over-year change
- +3.8pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.9% | +3.8pp |
| FY2024 | 2024-12-31 | 1.1% | +13.0pp |
| FY2023 | 2023-12-31 | -11.8% | +53.4pp |
| FY2022 | 2022-12-31 | -65.3% | -11.9pp |
| FY2021 | 2021-12-31 | -53.4% | — |
EBITDA Margin vs competitors
How TALK compares with its peers on the latest reported figures
- TALK's LTM Mar 2026 EBITDA Margin of 2.6% is the 5th highest of the 10 companies compared; the peer median is 1.2%.
- Its year-over-year change of +0.4 pp is the 8th highest of 9, against a peer median of +8.6 pp.
- Over three fiscal years its change of +70.2 pp compares with a peer median of +2.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | 66.7% | +35.3 pp | +24.1 pp |
| LTM Mar 2026 | 43.8% | +19.9 pp | +89.5 pp | |
| LTM Mar 2026 | 23.1% | +13.2 pp | +6.6 pp | |
| LTM Mar 2026 | 2.8% | +4.1 pp | -1.9 pp | |
| LTM Mar 2026 | 2.6% | +0.4 pp | +70.2 pp | |
| LTM Mar 2026 | 1.2% | -11.7 pp | -1.1 pp | |
| LTM Mar 2026 | 0.5% | +1.0 pp | -0.9 pp | |
| LTM Mar 2026 | -3.0% | +46.3 pp | -16.1 pp | |
| LTM Mar 2026 | -58.2% | +0.7 pp | +19.4 pp | |
| LTM Dec 2025 | -101.1% | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding TALK) | 1.2% | +8.6 pp | +2.8 pp | |
Competitors are the stored peer set for TALK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 113.67M | 119.57M | 150.05M | 187.59M | 228.87M |
| Cost of Revenue | 46.9M | 59.23M | 75.67M | 101.76M | 130.52M |
| Gross Profit | 66.77M | 60.34M | 74.38M | 85.84M | 98.35M |
| Gross Margin | 58.7% | 50.5% | 49.6% | 45.8% | 43.0% |
| Research & Development | 15.92M | 21.66M | 17.57M | 10.51M | 9.54M |
| Selling, General & Admin | 135.41M | 109.11M | 73.86M | 73.28M | 75.57M |
| Operating Expenses | 160.7M | 137.36M | 97.59M | 90.33M | 95.2M |
| Depreciation & Amortization | 1.97M | 1.36M | 1.2M | 859K | 2.88M |
| EBITDA | (60.72M) | (78.06M) | (17.77M) | 2.1M | 11.24M |
| EBITDA Margin | -53.4% | -65.3% | -11.8% | 1.1% | 4.9% |
| Operating Income | (93.92M) | (77.02M) | (23.21M) | (4.5M) | 3.15M |
| Operating Margin | -82.6% | -64.4% | -15.5% | -2.4% | 1.4% |
| Interest Income | 31.23M | 3.74M | 4.25M | 5.74M | 5.22M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 31.23M | (2.39M) | 4.25M | 5.74M | 5.22M |
| Income Before Tax | (62.7M) | (79.42M) | (18.96M) | 1.24M | 8.37M |
| Pre-Tax Margin | -55.2% | -66.4% | -12.6% | 0.7% | 3.7% |
| Income Tax Expense | 47K | 254K | 218K | 94K | 574K |
| Net Income | (62.74M) | (79.67M) | (19.18M) | 1.15M | 7.79M |
| Net Margin | -55.2% | -66.6% | -12.8% | 0.6% | 3.4% |
| EPS (Basic) | (0.72) | (0.51) | (0.12) | 0.01 | 0.05 |
| EPS (Diluted) | (0.72) | (0.51) | (0.12) | 0.01 | 0.04 |
| Weighted Avg Shares | 154.08M | 156.89M | 165.04M | 168.91M | 168.43M |
| Weighted Avg Shares (Diluted) | 154.08M | 156.89M | 165.04M | 176.5M | 173.75M |
Talkspace, Inc.
NASDAQ:TALK
Intrinsic Alpha fair value
Locked
Current Price
$5.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.